Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
PureTech Health PLC on Wednesday said that it has started the next stage of trials for LYT-300, in order to test whether the therapy could be used to treat anxiety disorders.
The Phase 2a proof-of-concept clinical trial will test LYT-300 in healthy volunteers using a validated clinical model of anxiety.
LYT-300 is the Boston, US-based biotherapeutics company’s candidate for the potential treatment of neurological and neuropsychiatric disorders, including anxiety disorders and postpartum depression.
The therapy has already gone through one stage of testing.
In December last year, PureTech celebrated positive topline results from its completed, multi-part Phase 1 study of LYT-300.
Data from the study showed that oral administration of LYT-300 achieved blood levels of allopregnanolone at or above those associated with therapeutic benefit in post-partum depression, and nine times greater than orally administered allopregnanolone, based on third-party data.
‘We believe that our Glyph technology platform is positioned to unlock the therapeutic potential of a range of molecules, beginning with allopregnanolone, and we look forward to the results of this study as well as the initiation of a study with LYT-300 in postpartum depression later this year,’ said Chief Innovation Officer Eric Elenko.
PureTech shares were trading 0.9% higher at 234.00 pence each in London on Wednesday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.